POS-354 WORSENING KIDNEY DISEASE INFLUENCES THE EFFICACY OF ERTUGLIFLOZIN ON GLUCOSURIA-MEDIATED ENDPOINTS BUT DOES NOT INFLUENCE THE EFFICACY ON NATRIURESIS-RELATED ENDPOINTS: PRESPECIFIED ANALYSES FROM VERTIS CV

• D. Cherney,
• B. Charbonnel,
• F. Cosentino,
• R.E. Pratley,
• S. Dagogo-Jack,
• W.J. Shih,
• D.K. McGuire,
• R. Frederich,
• M. Maldonado,
• J. Liu,
• A. Pong,
• C. Liu,
• C.P. Cannon

Affiliations

D. Cherney

Toronto General Hospital, Division of Nephrology, Toronto, Canada

B. Charbonnel

University of Nantes, Department of Endocrinology and Diabetes, Nantes, France

F. Cosentino

Karolinska Institute and Karolinska University Hospital, Unit of Cardiology, Stockholm, Sweden

R.E. Pratley

AdventHealth Translational Research Institute, Diabetes Institute, Orlando, United States

S. Dagogo-Jack

University of Tennessee Health Science Center, Division of Endocrinology and Diabetes and Metabolism, Memphis, United States

W.J. Shih

Rutgers School of Public Health and Rutgers Cancer Institute of New Jersey, Department of Biostatistics and Epidemiology, New Brunswick, United States

D.K. McGuire

University of Texas Southwestern Medical Center & Parkland Health and Hospital System, Division of Cardiology, Dallas, United States

R. Frederich

Pfizer Inc., Research and Development, Collegeville, United States

M. Maldonado

Merck Sharp & Dohme Limited, Diabetes and Endocrinology, London, United Kingdom

J. Liu

Merck & Co. Inc., Clinical Research, Kenilworth, United States

A. Pong

Merck & Co. Inc., Biostatistics, Kenilworth, United States

C. Liu

Merck & Co. Inc., Biostatistics, Kenilworth, United States

C.P. Cannon

Harvard Medical School, Cardiovascular Division, Boston, United States